Complete title: A PHASE 1B, MULTICENTER, TWO-PART, OPEN-LABEL STUDY OF DS-8201A, AN ANTI-HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR-2 (HER2)-ANTIBODY DRUG CONJUGATE (ADC), IN COMBINATION WITH NIVOLUMAB, AN ANTI-PD-1 ANTIBODY, FOR SUBJECTS WITH HER2-EXPRESSING ADVANCED BREAST AND UROTHELIAL CANCER
| Research Study Number | RG1003438 |
| Principal Investigator | Evan Yu, MD |
| Phase | I |
Participants will receive this study drug along with a cancer drug that is already being used, called nivolumab.
The study will be done in two parts:
Part 1 is to identify the recommended dose to use for treatment.
Part 2 is to find out how well the combination works, and how safe and tolerable it is.
Other eligibility criteria may apply.
| Research Study Number | RG1003438 |
| Contact | Seattle Cancer Care Alliance Intake Office |
| Telephone | 800-804-8824 / 206-606-1024 |
Keywords: Breast Cancer; Neoplasms, Glandular and Epithelial; Urothelial Cancer; Carcinoma, Transitional Cell
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.
Please remember:
Talk to your health care providers first before making decisions about your health care.
Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.